The pathophysiological relationship between scleroderma and malignancy remains poorly understood.
a non-smoker with scleroderma. Since then, associations with tumours predominantly aVecting the lung, breast and haematological systems have been most frequently reported [6, 7] . Several cohort studies have been performed to explore this risk [8] [9] [10] . The Wrst inXuential study consisting of 233 Swedish patients from Rosenthal et al. [7] discovered a relative risk of 2.5 for all malignancies, especially for lung, skin and haematological cancers. Similar Wndings were reiterated by Hill et al. [8] in 2003. Generally, studies have noted high concurrence rates ranging between 2.6 and 19%, and standardised incidence ratios (SIRs), i.e. ratio of observed malignancies to that expected, varying from 1.5 to 5.1 [7, 8] . However, from one of the largest studies from Detroit involving 538 patients, Chatterjee in 2005 found no increase in risk [9] . To our knowledge, no such study based within UK had previously been performed. As such, the risk and pathophysiological relationship between scleroderma and malignancy within our population is still unclear.
Aims and objectives
We aimed to determine if scleroderma patients within our local South West England population had an increased risk of malignancy and whether there were any identiWable predictors of malignancy.
Materials and methods
We identiWed all patients with a diagnosis of scleroderma within a local South West English population of Bristol from a pre-existing scleroderma database encompassing a population of approximately 550,000. Patients were ascertained by scanning through coding databases of each regional healthcare trust for patients with scleroderma ICD codes who were aYliated with the Bristol region, e.g. for treatment, follow-up and referrals to other specialists. Patients who were known to be deceased at the time of the audit or those with incomplete case notes were excluded from the study. Patients with malignancy were veriWed by contacting each patient's general practitioner. Case notes were scrutinised for key features including age, sex, scleroderma subtype, duration of illness, malignancy type, autoantibody proWle and use of disease-modifying antirheumatic drugs (DMARDs). Patients were classiWed into three categories: 'diVuse', 'limited' and 'overlap'. Patients were excluded if the diagnosis was unclear. Scleroderma categorisation was based on specialist diagnosis, and where unavailable, aided by demarcating parameters devised by LeRoy et al. [11] . Scleroderma onset was deWned as the earliest symptoms of proximal cutaneous sclerosis, and malignancy onset as the initial onset of symptoms. Malignancy prevalence rates from our follow-up period were compared with expected malignancy Wgures obtained from age-and sex-stratiWed regional prevalence data provided by the South West Cancer Intelligence Service registry. Patients with carcinoma in situ or without tissue diagnosis were not included in the analysis. Comparative analysis was performed using a web-based statistical package (Simple Interactive Statistical Analysis) [12] . ConWdence intervals (95% CIs) for relative risks (RRs) were approximated using the Poisson distribution, with two-tailed p values calculated using paired Student t test. Fisher's exact test with two-tailed p values was used for hypothesis testing wherever integers were available for comparison between two data subsets. Results were regarded as statistically signiWcant when p · 0.05, and of borderline signiWcance when 0.05 < p · 0.10.
Results
We identiWed 68 patients with scleroderma. The study population consisted of 58 females and 10 males, with a median age of 57.5 years (SD: 3.6, range: 17-86) ( Table 1) . Forty-eight patients were classiWed under 'limited' (70.6%) and 12 under 'diVuse' (17.6%). Eight patients were classiWed under 'overlap' (11.8%) due to additional elements of systemic lupus erythematosus (n = 3), mixed connective tissue disease (n = 2), polymyositis (n = 1), dermatomyositis (n = 1) and rheumatoid arthritis (n = 1).
In total, 15 malignancies were identiWed in 15 patients. Malignancies were seen in 25% of the diVuse group, 22.9% of the limited group and 12.5% of the overlap group. The overall concurrence rate of scleroderma and malignancy from our study population was 22.1% (95% CI 14.1-35.4%). The observed cancer sites were of the breast (5), haematological system (5), skin (4) and an adenocarcinoma of unknown primary (ACUP) (Fig. 1) . Of the haematological malignancies, there were two patients with myeloma and three with non-Hodgkin lymphomas (NHLs), which consisted of diVuse large B cell lymphoma, solitary IgM plasmacytoma and mucosa-associated lymphoid tissue lymphoma of the thyroid. Within our malignancy subgroup, the mean age of scleroderma diagnosis was 49.1 years (SD = 14.2). In 86.7% of patients (n = 13), malignancy was diagnosed after the onset of scleroderma (mean = 6.9 years). Two patients with breast cancer and malignant melanoma were diagnosed prior to the onset of scleroderma. We found no signiWcant correlation between malignancy type and the onset between scleroderma and malignancy. Demographic, clinical and serological comparisons conducted between the malignancy and control groups are summarised in Table 2 . Patients with unknown data for any of the listed Welds were omitted from analysis. Old age (>70 years) was a statistically signiWcant risk factor for acquiring scleroderma-associated malignancy (p = 0.02). No signiWcant diVerences were seen between the two groups in terms of organ involvement, autoantibody proWles and DMARD use.
Age-and sex-adjusted RRs for developing malignancies are summarised in Table 3 . The overall relative risk for developing malignant neoplasms was 3.15 (95% C.I. 1.77-5.20) and was considered statistically signiWcant (p = 0.01). This Wgure was high despite accommodating for malignancies with high prevalences within the general population that were not seen within our small cohort, for example, lung, gastrointestinal and gynaecological cancers. Consistent with previous literature, there was a statistically signiWcant increase in occurrence of haematological malignancies associated with scleroderma (RR = 18.51, 95% C.I. 6.01-43.19, p = 0.03).
The malignant potential according to scleroderma subtype has also been explored. Previous studies have consistently demonstrated higher risks of malignancy in patients with diVuse scleroderma in comparison to limited scleroderma and other forms of the disease [8] . From our cohort, the relative risk of malignancy in patients with diVuse scleroderma was 3.54, which was greater than that observed in limited scleroderma (RR = 3.13) and other forms of the disease (RR = 2.52). Due to the small number of patients with diVuse scleroderma and other forms of the disease, these risks did not achieve statistical signiWcance (p = 0.2 and p = 0.6, respectively). However, in a suYciently sized group of 48 patients with limited scleroderma, the relative risk of 2.52 for concurrent malignancy was signiWcant (p = 0.03) ( Tables 3 and 4 ).
Discussion
Our results coincide with those from the landmark study of Duncan and Winkelmann [10] which reported breast and haematological malignancies as the most prevalent scleroderma-associated malignancies. A Danish study by Jacobsen et al. [13] reported malignancy as the primary cause of death in 19% of scleroderma patients, where cancers of the lung (43%), haematological system (13%) and breast (10%) were predominantly implicated. After excluding lung malignancies, which were not observed in our study, these observations relate to the most frequently aVected sites of malignancy as observed within our scleroderma cohort. Malignancies are thus important as they constitute a major cause of morbidity and mortality in scleroderma patients.
Despite our relatively small cohort, we did demonstrate a positive correlation between scleroderma and malignancy which was statistically signiWcant. However, several other limitations within our study require acknowledgement. This was a retrospective, cross-sectional analysis of current patients with scleroderma without applying a strict observation interval. Statistical analysis consisted of comparing standardised prevalence rates instead of standardised incidence ratios. The observation that a positive smoking history was signiWcantly less within the malignancy group (p = 0.02) may suggest bias in data collection, however, this may have been accountable for the absence of lung cancer cases seen in the cohort. The relative risk of malignancy in our cohort was generally higher than previously reported. Although this may be explained by the high prevalence of haematological malignancies within our cohort, it is possible that, due to a small sample size, small increases in malignancy cases can lead to disproportionate increases in relative risk. Furthermore, we speculate that if there had been more patients, p values for risks ascertained from subgroup analysis, e.g. by sex and scleroderma subgroups, may have become signiWcant.
The pathophysiology behind the potential association between scleroderma and malignancy is unclear, although we postulate that this involves dysregulation of molecular signalling pathways at an intracellular level. Of particular interest is the role of transforming growth factor-(TGF-), a ubiquitous proWbrotic cytokine, involved in the regulation of connective tissue proteins which is heavily overexpressed in sclerodermatous tissue. Dysregulated signalling of the TGF-and downstream SMAD pathways have been demonstrated to induce tumorigenesis [14] , and has been implicated in malignancies seen within our cohort, i.e. breast, skin and haematological malignancies [14] [15] [16] . Furthermore, it is recognised that malignant transformation may be a sequela of chronic tissue damage. This mechanism has traditionally been implicated in the aetiogenesis of lung cancers in scleroderma due to associated pulmonary Wbrosis, but may also be responsible for the development of cutaneous malignancies seen within our cohort. Interestingly, there were no patients with lung malignancies despite its reported frequency within the literature. We believe that this is partly due to the combination of low numbers of smokers and small numbers of patients with diVuse scleroderma which is typically associated with pulmonary involvement. The use of DMARDs in the management of scleroderma has been implicated as a potential contributory factor towards the development of malignancy. Cyclophosphamide has been linked with a 30-fold increase in risk of bladder cancers, and an overall two-to fourfold increase in haematological and skin malignancies [17] . Occasionally, malignancy may indirectly induce scleroderma as part of a paraneoplastic process. This has been observed in malignant carcinoid syndrome and also in POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes) syndrome, which most commonly occurs in patients with IgA plasmacytoma [18] . Interestingly, one patient within our cohort developed skin changes consistent with limited scleroderma as part of POEMS syndrome and was eventually diagnosed with IgM plasmacytoma 2 months later. In paraneoplastic scleroderma, processes driven by neoplasia are likely to be responsible. These processes have been postulated to involve abnormalities in antigen presentation, autoantibody genesis, disturbances of cellular immunity, cytokine imbalance, abnormal mediation of growth factors and hormones [19] .
Conclusion
From the Wrst population-based analysis of scleroderma patients in South West England, we have found that the prevalence of malignancy is increased in scleroderma, particularly with haematological malignancies. Patients who are elderly and those with limited disease should thus be closely scrutinized at follow-up appointments.
